Filing Flows › Alnylam Pharmaceuticals (ALNY) › Q3 2026
Alnylam Pharmaceuticals (ALNY) Q3 2026 earnings results (third quarter 2026)
10-Q filed Oct 29, 2026
Alnylam Pharmaceuticals (ALNY) reported revenue of $1.5B for the third quarter 2026 (Q3 2026), +17% from a year earlier and +13% from the quarter before. Operating margin was 23.7%, net earnings $2.2B (148.6% of revenue).
Alnylam Pharmaceuticals, Q3 2026: revenue $1.5B (+17% year over year), operating margin 23.7%, net earnings $2.2B, operating cash flow $341M. The chart follows the revenue to costs, profit and cash.
| Q3 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $1.5B | +13% | +17% |
| Operating profit | $346M | +49% | -6% |
| Net earnings | $2.2B | 13× | +641% |
| Operating cash flow | $341M | — | +15% |
| Free cash flow | $271M | — | -5% |
What changed
Revenue was $1.5B in Q3 2026, up 17% year over year and up 13% from the previous quarter. AMVUTTRA was the largest line at 78% of revenue. AMVUTTRA added $0.45B year over year (up 65%), 213% of the total change. Net revenues from collaborations declined 80%.
Operating profit was $0.35B, a 23.7% margin (down 5.7 points year over year). Operating profit fell $0.02B even though revenue rose $0.21B versus Q3 2025, so costs grew faster than sales. Total costs grew 26% against revenue growth of 17%. The fastest-growing cost line was Cost of revenue (+83%). Net earnings were $2.2B, up 641% year over year. The tax line was a benefit of $1.9B on pre-tax earnings of $0.30B.
Operating cash flow was $0.34B (up 15% year over year), 16% of net earnings. Non-cash charges added back $0.01B of depreciation and amortization and $0.08B of share-based compensation. Working capital and other items used $1.9B. Capital expenditures of $0.07B left free cash flow of $0.27B.
Questions
What was Alnylam Pharmaceuticals' revenue in the third quarter 2026?
Alnylam Pharmaceuticals (ALNY) reported revenue of $1.5B for the third quarter 2026 (Q3 2026), +17% from a year earlier and +13% from the quarter before.
Was Alnylam Pharmaceuticals profitable in the third quarter 2026?
Operating profit was $346M (23.7% of revenue) and net earnings $2.2B.